Inflammatory bowel disease (IBD) is characterized by activation of both the innate and adaptive immune system in genetically susceptible individuals, resulting in chronic intestinal inflammation. The triggers that initiate and perpetuate this continuous inflammation are the subject of much speculation and research, although the central role of the intestinal microbiota is recognized, and is even a target for treatment in some circumstances. The mainstay of modern IBD treatment is suppression of the immune response towards as yet unspecified antigens, and conventional therapy includes corticosteroids, 5-aminosalicylic acid (5-ASA), thiopurines and methotrexate. Reducing activity of specific mediators has proven efficacious, including adhesion molecules, such as the gut-homing integrin α 4 β 7 expressed on the surface of circulating immune cells, and cytokines, such as tumour necrosis factor α (TNF-α). This has been achieved using biologic agents including monoclonal antibodies. Recent discoveries in immunology and neuroscience have revealed that signals in the peripheral nervous system regulate inflammation, including levels of TNF-α. The understanding of the mechanisms of the neuro-immune communication involved in inflammation control in the gut is evolving, but is as yet incomplete. Clinical studies using implanted vagus nerve stimulators for treatment of IBD show encouraging results. Accordingly, the neural reflex control of inflammation is emerging as a potential therapeutic target in treatment of IBD. Here, we review current therapeutic options and neural reflex control of gut immunity in the context of intestinal inflammation.
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| INFLAMMATORY BOWEL DISEASE
The inflammatory bowel diseases (IBDs) are chronic inflammatory conditions often diagnosed in teenagers or young adults, and with a prevalence of approximately 1.6 million patients in the United States and 2.5 to 3 million in Europe.
1,2 IBD is broadly divided into two entities, Crohn's disease (CD), characterized by deep mucosal inflammation that can affect the entire gastrointestinal tract (GI), and ulcerative colitis (UC) with continuous superficial inflammation limited to the large intestine. Common symptoms are loose stools with blood and mucus, abdominal pain, and fatigue. CD is also associated with intra-abdominal and perianal fistulas, abscess formation, and intestinal strictures in the small bowel and colon. [3] [4] [5] [6] IBD patients with severe disease and long duration often have inadequate response to conventional treatment such as 5-aminosalicylate and corticosteroids, and the risk of colorectal cancer in patients with prolonged inflammation is evident. [7] [8] [9] [10] In Sweden, 14% of UC patients and 37% of CD patients are eventually subjected to major IBD-related surgical interventions. 11 Antibiotics and deviation of the faecal stream from the ileum into a stoma often alleviate the disease, underlining the central role of luminal microbiota in triggering the continuous inflammation. 5, 6 In this article, we will review the key inflammatory drivers of IBD and the neural control of inflammation. We will then relate this to the currently available treatments for IBD as well as the potential future treatment modality of vagus nerve stimulation.
| IMMUNE ACTIVATION IN IBD
Even though CD and UC share the clinical features of chronic intestinal inflammation, their pathogenic pathways may differ. Inflammatory innate and adaptive immune cells are produced in the bone marrow and access the inflamed mucosa through the blood. The innate immune system, that is circulating monocytes transforming into antigen-presenting macrophages once they reach the gut, and granulocytes are important for mucosal immune responses together with antigen-presenting dendritic cells (DC) resident in the gutassociated lymphoid tissue (GALT). This, "first line of defence," is immediately activated when intestinal mucosal integrity is breached by invading bacteria, providing a nonspecific immunity through the recognition of non-self surface structures that are common to several microbes. The subsequent antigen-specific activation of the adaptive immune cells elicits precise, antigen-directed responses from T and B cells allowing for efficient, targeted elimination of bacteria, pathogens as well as commensals that breach the intestinal barrier. [12] [13] [14] [15] [16] After entering GALT through binding of chemokine-receptor (CCR) CCR7 to ligands lining the high endothelial venules (HEVs) of the lymphatic tissue, naive lymphocytes are activated by DCs through antigen-presentation and co-stimulation. 17, 18 Retinoid acid released from the gut DCs induces the integrin α4β7 as well as the CCR9 in parallel with downregulation of CCR7 on activated T cells, which will be bound for the lamina propria (LP) of the intestinal wall. [18] [19] [20] These T cells reenter the circulation and α4β7 binds to intestinal postcapillary venules expressing the mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) while CCR9 recognizes the mucosal chemokine CCL25, allowing for adept gut-specific immune responses. 18, 21, 22 The spectrum of cytokines involved and subsequent activation of different immune cell populations varies between the different forms of IBD. [23] [24] [25] However, the intricate immunological characteristics of the different IBD entities are beyond the scope of this review.
| NEURAL CONTROL OF GUT

INFLAMMATION
Neural reflexes are important for homeostasis, for example regulating heart rate, body temperature and alimentation. Afferent nerves monitor physiology and the environment while efferent nerves signal to regulate important aspects of organ function and maintain homeostasis. 26, 27 Elevated levels of pro-inflammatory cytokines in the peritoneal cavity have been associated with increased electrical activity in the vagus nerve. [28] [29] [30] An example of a homeostatic reflex is the "inflammatory reflex." Signals in this reflex involve sensory and motor neurons in the vagus nerve, the splenic nerve, acetylcholine-releasing T cells, and immune cells that express the α7 nicotinic acetylcholine receptor subunit (a7nAChR) in spleen, see Figure 1 . 31, 32 In inflammation, the cholinergic neurotransmitter acetylcholine reduces release of pro-inflammatory cytokines from monocytes and macrophages. 33, 34 Electrical as well as pharmacological activation of components in the inflammatory reflex has been used in experimental models of disease and in human clinical trials to reduce release of pro-inflammatory cytokines and inflammation. 31, [35] [36] [37] The gastrointestinal tract is innervated by the vagus nerve (VN), connecting the central nervous system with visceral organs through one fifth of efferent and four fifths of afferent nerve fibres. 38 The functional mapping of the vagus nerve is not yet complete. Tracing studies show that efferent vagal neurons emanate from the dorsal motor nucleus of the vagus in the brain stem, and afferent neurons project to the adjacent nucleus tractus solitarius.
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The vagus nerve functionally connects with postganglionic neurons in the myenteric plexus as seen in Figure 1 .
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How the signal is further relayed to macrophages and dendritic cells in the intestinal wall is however not fully elucidated. Resident macrophages are found in the lamina propria and the muscular layer of the intestine, adjacent to the enteric nervous system. The principal neurotransmitter of the vagus nerve is acetylcholine, a neuratransmitter known to reduce release of pro-inflammatory cytokines in innate immune cells. 42 Interestingly, mice deficient in acetylcholine-producing T cells, which relay neural signals and also are involved in regulation of the vasculature, show alterations in the composition of the microbial diversity in the intestine. [43] [44] [45] However, the system is complicated and the role of other enteric signalling proteins such as nitric oxide and vasoactive intestinal peptide (VIP) remains to be clarified. [46] [47] [48] Signs of decreased vagus nerve activity have been observed in some inflammatory diseases, including rheumatoid arthritis (RA) and IBD. 49, 50 Experimental evidence in murine models indicates that the reflex control of gut inflammation is mediated by efferent vagus nerve signals to macrophages residing in the intestine, as well as by the inflammatory reflex, that is, through neuro-immune interactions in the spleen. 51, 52 The current understanding is that the cholinergic anti-inflammatory pathway to the gut is routed through two distinct pathways. One direct conduit involves efferent vagus neurons that directly target the myenteric plexus in the intestinal wall. Another route involves efferent vagus neurons that functionally synapse in the coeliac plexus. These signals are propagated by the adrenergic splenic nerve and relayed by acetylcholine-releasing T cells to α7nAChR + innate immune cells in the spleen. 48 Both pathways are likely to reduce macrophage release of pro-inflammatory cytokines through activation of α7nAChR, with subsequent engagement of Jak2 and STAT3, or cAMP and cAMP response element-binding Protein (CREB). 34, 44, [53] [54] [55] [56] [57] Thus, cholinergic neural signals reduce TNF-α release from macrophages and attenuate inflammation.
| KEY PRO-INFLAMMATORY ANTIGENS IN INFLAMMATORY BOWEL DISEASE REMAIN UNDEFINED
The antigens responsible for the initial activation of the intestinal immune system in IBD are still undefined, probably because a combination of several factors such as environmental triggers, luminal microbiota and genetic susceptibility is required to initiate intestinal inflammation, and the precise combination of these parameters is likely to vary between diseases and between individuals. Commensal or pathogenic bacteria are probably crucial for driving the chronic inflammation seen in IBD, especially in CD. 58, 59 Several individual species have been implicated in CD pathogenesis, including adherent-invasive Escherichia coli (AIEC) which colonizes the ileal mucosa in CD patients. 60, 61 In addition, Mycobacterium avium subsp paratuberculosis, which causes a zoonosis similar to CD (Johne's disease), is present more frequently in patients with CD, but clear evidence for a direct disease-causing role is lacking. 62, 63 A reduced abundance of Faecalibacterium prausnitzii, which produces the anti-inflammatory short chain fatty acid butyrate, could have an aetiological role in CD, supported by the established association between reduced mucosal F prausnitzii and subsequent post-surgical relapse in CD. [64] [65] [66] Low abundance F prausnitzii has also been demonstrated in faecal and colonic mucosal samples of siblings of patients with CD, indicating a role in CD-risk and pathogenesis. 67, 68 Although antibiotics may be beneficial in the treatment of IBD, the evidence for specific disease-causing species is only circumstantial. 69, 70 It has been speculated that a dysfunctional mucosal barrier plays a pathogenic role by promoting exposure of lamina propria immune cells to commensal microbiota. Intestinal permeability is significantly increased in 27% of first degree relatives to IBD patients, as measured by lactulose:mannitol ratio in urine, suggesting an inherited deficient mucosal integrity. 71 Furthermore, increased intestinal permeability has been shown to predict flares before symptoms occur in CD patients. 72 Reports have also identified genetic variants associated with barrier integrity, for example mutations of MDR1 (multidrug resistance 1) which causes attenuated production of glycoprotein 170 and therefore reduced protection against bacterial products. 73, 74 Similarly, deficient production of defensins from Paneth-cells within the intestinal epithelium is linked to genetic variants of the susceptibility locus ATG16L1 and has been associated with CD. 75 Another common hypothesis of IBD pathogenesis is that IBD primarily is a result of immune system dysregulation. An important loss-of-function gene polymorphism associated with CD has been identified in the CARD15 (caspase-recruitment domain 15) coding for nucleotidebinding oligomerization domain-containing protein 2 (NOD-2), implicating a dysfunction in an intracellular pathogen-associated molecular pattern receptor for a common bacterial antigen, muramyl dipeptide. [76] [77] [78] One study has shown reduced immune response towards subcutaneously injected E coli in CD patients compared to healthy controls, supporting the idea that abrogated clearance of invading bacteria contributes to disease development. 79 In addition, macrophages from CD patients show decreased cytokine release, most prominently IL-8 but also IL-1β compared to cells from non-IBD controls. 80 The dysfunctional macrophages have been associated with polymorphisms in the IRGM and ATG16L1 genes. The abrogated cytokine release may be caused by dysfunctional posttranslational modifications resulting in lysosomal degradation, instead of extracellular release of central cytokines and therefore cause a reduced efficacy in bacterial clearance.
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| CURRENT IBD TREATMENT
Given that advances in the understanding of IBD pathogenesis have not yet identified a curative therapeutic target, the current treatment of IBD focuses on reducing inflammatory activity by attenuating proliferation and pro-inflammatory activity of immune cells. The modern therapeutic arsenal comprises corticosteroids, 5-ASA, thiopurines, methotrexate and monoclonal antibody biologic agents. These different drugs modulate various cellular functions, and by combining different therapeutic modalities, a sufficient disease control may be achieved while maintaining the risk of adverse events at an acceptable level.
| Glucocorticosteroids
The anti-inflammatory effects of glucocorticosteroids (GCS) are mediated through the intracellular glucocorticoid receptor, which migrates to the cell nucleus within 20 minutes of ligand/receptor binding. In the nucleus, the glucocorticoid/receptor complex binds to positive glucocorticoid-responsive elements in the DNA and induces synthesis of anti-inflammatory proteins, so-called transactivation. 83, 84 The glucocorticosteroid/receptor complex also binds to negative glucocorticoid-responsive elements in the DNA, inhibiting gene expression of cytokines such as IL-1 and IL-2. 84 In addition, transrepression, which involves interaction of the corticosteroid/receptor complex with proinflammatory transcription factors in the genome, reduces transcription of activator protein 1 and NF-κB. 85 The corticosteroid/receptor complex also competitively inhibits proinflammatory co-activators in the cell nucleus. All these negatively regulating mechanisms lead to reduced expression of cytokines such as IFN-γ and TNF-α.
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| 5-Aminosalicylate
5-Aminosalicylate drugs (5-ASA) were introduced almost seven decades ago in the form of sulfasalazine. The original drug consisted of a combination of an antibiotic, sulfapyridine and 5-ASA. Thirty-five years later, the demonstration that the anti-inflammatory effect was mediated by the 5-ASA component led to the development of alternative formulations and improved side-effect profile. 87 A reduction in local cytokine production in the intestinal mucosa by 5-ASA has been observed, including reduction of IL-1β, IL-2 and IFN-γ. 5-ASA inhibits the transcription of epithelial NF-B by modulating the RelA/p65 phosphorylation. In addition, 5-ASA blocks the pro-inflammatory effect of TNF-α on mucosal immune cells and reduces the local production of prostaglandins and leukotrienes. 87, 88 More recently, 5-ASA has been reported to be a strong agonist of the PPAR-γ receptor family, that is the same receptor that is targeted by the modern anti-diabetic glitazones. Ancillary to the regulation of lipid metabolism and insulin sensitivity, PPAR-γ receptor agonists also inhibit the expression of IL-1β and TNF-α in addition to a number of chemokines and adhesion molecules involved in the inflammatory process. Furthermore, PPAR-γ reduces the mucosal proliferation of inflammatory cells probably by inducing apoptosis.
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| Thiopurines
The anti-inflammatory effect of thiopurines (azathioprine and 6-mercaptopurine) and their side-effects are mainly attributable to the actions of the mutual metabolite 6-thioguanine, which replaces guanine in the replicating DNA of proliferating immune cells, thereby suppressing the proliferation of leucocytes and lymphocytes. In addition, thiopurine methyltransferase (TPMT) methylates thiopurines into methylmercaptopurine ribonucleotides that exert an immediate inhibition of the purine synthesis in leucocytes.
Furthermore, methyl nitroimidazole, a by-product of the metabolism of azathioprine (but not 6-mercaptopurine), has immunosuppressive characteristics of unclear mechanism. 91, 92 A discovery explaining the immunosuppressive effect of thiopurines is the metabolite 6-thioguanine-triphosphate (6-TGTP) which blocks Racl-signalling mediated through CD28 stimulation by lymphocytes, leading to apoptosis of the antigen-specific and therefore activated T cells, while quiescent T cells with no antigen-specific T cell receptor are unaffected. This effect is executed through inhibition of STAT3 and NF-κB and may explain the delayed response seen in IBD patients after initiation of thiopurines since full immunosuppression cannot be expected until two to three months of treatment. 93 Animal studies have shown that thiopurine-induced apoptosis requires repeated exposure of activated T cells to antigen. This programmed cell-death extended over time in activated T cells in combination with the 6-thioguanine substitution of guanine in replicating DNA eventually results in T cell depletion and abrogation of the inflammatory process. 
| Methotrexate
The principal mechanism of methotrexate, which was originally an anti-cancer drug, is mediated via intracellular inhibition of folic acid metabolism. This leads to a reduced conversion of homocysteine to methionine, thereby suppressing DNA-replication. The risk of adverse effects such as leukopenia, anaemia and stomatitis is mitigated by supplemental folic acid. Surprisingly, the anti-inflammatory effect of methotrexate is maintained despite folic substitution, which raises the question of alternative mechanisms of action. 95 One hypothesis is that methotrexate blocks the metabolism of aminoimidazole carboxamide ribonucleotide (AICAR), leading to reduced purine synthesis and accumulation of anti-inflammatory adenosine. 96 
| Monoclonal antibodies directed against
TNF-α
The mainstay of monoclonal antibody therapy in IBD is inhibition of TNF-α, a key cytokine in intestinal inflammation. TNF-α is expressed on immune cells as a transmembrane precursor (tmTNF), which is converted by TNF-α-converting enzyme to soluble TNF-α (sTNF). Monocytes/ macrophages are key producers of TNF-α, but T cells, granulocytes and stroma cells are also important sources of the cytokine. Both membrane-bound and soluble TNF-α are ligands to TNF-receptors I and II. [97] [98] [99] Monoclonal antibodies neutralize the soluble TNF-α, thereby reducing the pro-inflammatory capacity of mainly the innate immune system. However, in IBD a number of additional mechanisms of action seem to be more important than the clearance of soluble TNF-α. 99 Anti-TNF antibodies bind to transmembrane TNF-α. This will result in antibody-dependent cell-mediated cytotoxicity (ADCC), that is, cells with Fc-ɣ-receptors such as macrophages, DC and Natural Killer (NK) cells will bind to the monoclonal antibody and kill the antibody-targeted immune cell. Surface-bound monoclonal antibodies will also activate the complement cascade effecting a general T cell lysis. An additional proposed mechanism is so-called reversed signalling, meaning that monoclonal antibodies such as infliximab/adalimumab/golimumab will function as a ligand for the tmTNF, initiating a reverse phosphorylation signal back into the host cell which activates apoptosis, through the caspase-3-signalling pathway. This reversed signalling has also been shown to suppress cytokine release of TNF-α, IL-1β, IL-10 and IL-12. 100,101 Thus, the anti-TNF-antibodies target the innate as well as the adaptive immune system probably through binding to membrane-bound TNF-α. An additional tentative anti-inflammatory mechanism of TNF-inhibition is induction of M2-type macrophages with wound-healing capabilities, which has been seen in IFX and adalimumab assays. 102, 103 This finding has been supported by the clinical study observation that TNFi induction of regulatory macrophages was more evident in endoscopic responders compared to non-responders treated with IFX. 
| Monoclonal antibodies directed against α4β7 integrin
Another group of biologic treatments target the process of leucocyte adhesion and egress from the blood. Vedolizumab is a humanized antibody directed against the α4β7 integrin expressed by B and T cells that are homing to the gut. 104 The interaction between α4β7 integrin and its endothelial ligand, MAdCAM-1, is crucial during the process of leucocyte tethering, rolling and diapedesis. 105 The expression of MAdCAM-1 in gut and gut-associated lymphoid tissue permits compartmentalization of the immune response, restricting extravasation of lymphocytes to their intended site of action. Vedolizumab only interacts with the α4β7 heterodimer, thereby maintaining gut specificity. 104 In addition to lymphocytes, circulating CD16+ monocytes express α4β7, which may explain the reduced frequency of mucosal M2 macrophages in anti-α4β7-treated mice 106 
| Monoclonal antibodies directed against
IL-12 and IL-23
Further molecules targeting pro-inflammatory cytokines have been investigated in IBD. Notably, ustekinumab, which recognizes the p40 subunit common to both the IL-12 and IL-23 pro-inflammatory cytokines, is an established treatment of psoriasis and psoriatic arthritis. Since 2016, it has also been registered for the treatment of CD, regulating inflammation by inhibiting the two cytokines responsible for the Th1 and Th17 response, seen in IBD.
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6 | TREATING CD BY VAGUS
NERVE STIMULATION
In light of the insights into the neural control of inflammation and the findings that electrical vagus nerve stimulation (VNS) can be used to reduce levels of proinflammatory cytokines, including TNF-α, in inflammation, VNS is currently being tested in clinical trials for the treatment of inflammatory diseases. 37, 109, 110 Patients are implanted with a pacemaker-like stimulator device with a connecting cable tunnelled under the skin to the neck which is connected to an electrode wrapped around the left vagus nerve. In a clinical trial of VNS in patients suffering from RA, symptoms were reduced 42 days after treatment onset as was the ex vivo blood TNF-α release in response to inflammatory stimuli. As the VNS was stopped, symptoms worsened and the TNF-α response returned to baseline, 37 supporting the observations from numerous animal studies that VNS can reduce cytokine release and inflammation. 26 In IBD, results from clinical studies using VNS are still limited. Two studies have presented final or preliminary clinical results on VNS in patients with active CD. Bonaz et al reported a 6-month follow-up study in seven patients with CD, two with ongoing azathioprine treatment and the remaining five without concomitant therapy. 109 At baseline, all patients had Crohn's disease endoscopic inflammation score (CDEIS) ≥7. The VNS protocol in this study used an electrical current of 1.25 mA at a frequency of 10 Hz and pulse width 500 µs, in a continuous pattern of 30 seconds ON and 5 minutes OFF during a 6-month follow-up. Crohn's disease activity index (CDAI) and CDEIS were evaluated after 6 months continuous treatment. Two patients left the study early due to worsening of disease. The remaining five patients showed improvement of CDAI and four of these reached clinical remission (CDAI < 150) at end of study. At six months, all were in endoscopic remission (CDEIS < 6). All five patients reported reduced pain reflected by a decrease in mean VAS score from mean 3.5 to 1.6 after 6 months. No device-related major safety issues were reported. The study authors concluded that VNS is feasible for treatment of gut inflammation, and that the observed reduction of CDAI is encouraging. 109 In an ongoing clinical trial, 16 patients with CD and refractory to biologic treatment targeting TNF-α and/or integrin α4β7 were implanted with a vagus nerve stimulator. 110 Half of the cohort was treated with VNS as an add-on to baseline biologics and the remaining patients received VNS treatment as monotherapy. In this study, electrical VNS was delivered in minutes-long episodes once or four times daily and the clinical response evaluated at 16 weeks. Improvement in clinical scores was observed according to preliminary data from the study presented in abstract form, but a comprehensive report is still awaited. 110 The observations in these clinical trials of VNS in CD are important, because the efficacy of the currently available pharmacological therapy is not adequate in a proportion of patients and there is a great need for additional alternatives. Although the improvement of clinical and laboratory indicators reported in these studies is interesting and encouraging, the data available so far are too limited to determine how useful the current technology for electrical VNS is in treatment of CD. Moreover, the optimal parameters for electrical stimulation of the vagus nerve for efficacious treatment of inflammation, including inflammatory bowel disease, have not been determined. The stimulation protocols currently in use are largely based on empirical data. Importantly, the implantation and use of the vagus nerve stimulator seem safe and a proportion of the patients included in the studies improved in response to the intervention. Therefore, the convincing experimental data on inflammation control by VNS in animals together with the reported observations in clinical studies warrant further exploration of VNS as a treatment option in IBD in the context of clinical trials.
| CONCLUSION
Inflammatory bowel disease is a disease characterized by significant symptomatic burden caused by chronic intestinal inflammation. Currently available treatments improve symptoms and reduce inflammatory activity, but not always to a satisfactory degree. New insights into neural control of inflammation open new avenues of potential treatment. Clinical studies on VNS in IBD are yet limited, but observations are encouraging. It will be important to conduct clinical trials of electrical VNS for treatment of CD and other gastrointestinal diseases marked by excessive inflammation to elucidate these novel anti-inflammatory pathways with therapeutic potential.
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